Gynecologic Oncology Reports最新文献

{"title":"Adrenal insufficiency after megestrol acetate for fertility-sparing treatment of endometrial cancer","authors":"Lauren Clarfield , Laura Diamond , Soyoun Rachel Kim , Shima Deljoomanesh , Nashwah Taha , Shereen Ezzat , Eleni Dimaraki , Sarah E. Ferguson","doi":"10.1016/j.gore.2025.101961","DOIUrl":"10.1016/j.gore.2025.101961","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101961"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Themes, perspectives, and educational quality of content related to #PapSmears on TikTok","authors":"Stephany Amezcua ,&nbsp;Matthew W. Lee ,&nbsp;Laurel S. Aberle ,&nbsp;Katelyn B. Furey ,&nbsp;Xiaoyue Mona Guo","doi":"10.1016/j.gore.2025.101964","DOIUrl":"10.1016/j.gore.2025.101964","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate TikTok videos with the hashtag #PapSmear and analyze their educational quality, themes, tone, creator, and engagement metrics.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis of the top 150 TikTok videos with #PapSmear was conducted in September 2023. Videos were evaluated by four independent reviewers for engagement metrics, video topic, intent, tone, creator, and themes. The educational quality of videos was assessed using the brief DISCERN tool. Statistical analyses were performed to examine differences and relationships across groups.</div></div><div><h3>Results</h3><div>Among the 150 videos reviewed, 75.3 % focused on Pap smears, while 24.7 % discussed pelvic exams. Patients created 60.7 % of videos while healthcare providers contributed 39.3 %. Videos created by healthcare providers were more likely to be neutral or positive in tone and focus on educational content. Videos created by patients tended to have a negative tone, often focusing on personal experiences or comedy. Negative tones were significantly associated with higher engagement by “likes” and “shares” compared to neutral and positive tones. DISCERN scores were low across all videos. Healthcare provider videos did not score significantly higher than patient-generated content (p &gt; 0.05). 10 % (n = 15) of videos addressed trauma related to a Pap smear or pelvic exam.</div></div><div><h3>Conclusion</h3><div>Our analysis of the top 150 TikTok videos with #papsmear shows low educational quality across all creators, highlighting the difficulty of providing accurate health information on social media. To improve the quality and impact of health communication on social media, healthcare professionals might consider integrating relatable storytelling and appropriate humor while still prioritizing medical accuracy and trauma-informed messaging.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101964"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from plastic and reconstructive surgery wound specialists in managing complex vaginal and vulvar toxicities following radiation therapy","authors":"Ovya Ganesan ,&nbsp;Stephanie M. Mueller ,&nbsp;Diana Miao ,&nbsp;M Aiven Dyer ,&nbsp;Natalie Cain ,&nbsp;Colleen M. Feltmate ,&nbsp;Dennis P. Orgill","doi":"10.1016/j.gore.2025.101966","DOIUrl":"10.1016/j.gore.2025.101966","url":null,"abstract":"<div><h3>Objective</h3><div>Radiation therapy is essential for treating vaginal and vulvar cancers but can cause chronic pain, sexual dysfunction, infections, and delayed wound healing. These complications profoundly impact survivors’ quality of life and may impede cancer-directed treatment in recurrent disease. We describe a multidisciplinary approach involving Plastic and Reconstructive Surgery, Gynecologic Oncology, and Radiation Oncology for managing complex radiation-induced wounds.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed two patients with severe vaginal/vulvar radiation wounds treated at a tertiary wound care center.</div></div><div><h3>Results</h3><div>Case 1: A 71-year-old woman with vulvar squamous cell carcinoma (VSCC) underwent vulvectomy and adjuvant chemoradiation, developing acute radiation dermatitis. Recurrent VSCC required further surgery, and reconstruction was complicated by wound necrosis, which was treated with debridement, quarter-strength sodium hypochlorite and advanced dressings. Following a third vulvectomy for further recurrence, she again demonstrated impaired wound healing. Despite ongoing management, cancer persists.</div><div>Case 2: A 73-year-old woman with locally advanced endometrial adenocarcinoma received chemotherapy, external radiation, brachytherapy, hysterectomy with bilateral salpingo-oophorectomy, and stereotactic radiation for bone metastasis. Two years post-radiation, she developed vaginal necrosis, which was managed with hypochlorous acid solution, sharp debridement, and hyperbaric oxygen therapy. She recently enrolled in a clinical trial for persistent cancer.</div><div>In both cases, wound complications delayed optimal cancer-directed therapy.</div></div><div><h3>Conclusion</h3><div>These cases highlight the importance of a multidisciplinary strategy to manage severe radiation-induced vaginal/vulvar wounds. Focused on pain control, odor reduction, and optimizing the wound environment, care is often palliative given disease complexity, underscoring the challenges in balancing wound healing with ongoing cancer treatment.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101966"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical resection and sentinel lymph node evaluation of mammary-like adenocarcinoma of the vulva (MLAV) with somatic BRCA1 mutation","authors":"Lilla Markel ,&nbsp;Lidys Rivera ,&nbsp;A. Ordobazari ,&nbsp;Ardeshir Hakam ,&nbsp;Wilfredo Lorenzo ,&nbsp;Mitchel S. Hoffman ,&nbsp;Robert M. Wenham ,&nbsp;Monica Avila","doi":"10.1016/j.gore.2025.101957","DOIUrl":"10.1016/j.gore.2025.101957","url":null,"abstract":"<div><h3>Background</h3><div>Mammary-like gland adenocarcinoma of the vulva is a rare and aggressive form of vulvar cancer with histopathologic resemblance to breast cancer. This rare type of vulvar cancer develops from primary metaplasia of mammary-like anogenital glands, more recently discovered anatomic components of the anogenital region.</div></div><div><h3>Case presentation</h3><div>We present a 77-year-old African-American female with a six-month history of painless, left lower vulvar lesion referred to our cancer center following confirmatory biopsy of invasive mammary type adenocarcinoma. Preoperative PET CT demonstrating focal avidity (SUV 7.8) in the vulvar region with no evidence of metastatic disease. She underwent exam under anesthesia, left radical vulvar excision with primary closure, left inguinal sentinel lymph node mapping and biopsy for a TNM stage of T2N0M0 and vulvar FIGO stage IB grade 2. Somatic testing was significant for a BRCA1 mutation (variant p.S770, c.2309C&gt;G).</div></div><div><h3>Conclusion</h3><div>Mammary-like gland adenocarcinoma of the vulva is a rare but aggressive neoplasm that presents diagnostic challenges due to its resemblance to breast carcinoma. Radical resection and sentinel lymph node assessment is feasible. Melanocytic skin types pose a unique set of differences regarding detection, diagnosis and potential genomic variations such as BRCA1 mutation in our patient. Genetic and genomic assessments should be considered to further guide optimal therapeutic options.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101957"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tamoxifen for nodal recurrence of serous borderline ovarian tumour − a case report","authors":"Alyssia Guarneri ,&nbsp;Xing Zeng ,&nbsp;Reitan Ribeiro ,&nbsp;Shuk On Annie Leung ,&nbsp;Victoria Mandilaras ,&nbsp;Basile Tessier-Cloutier ,&nbsp;Lili Fu ,&nbsp;Tuyet Nhung Ton Nu ,&nbsp;Lara Richer ,&nbsp;Lucy Gilbert ,&nbsp;Laurence Bernard","doi":"10.1016/j.gore.2025.101960","DOIUrl":"10.1016/j.gore.2025.101960","url":null,"abstract":"<div><h3>Background</h3><div>Serous borderline ovarian tumours (SBTs) are rare epithelial neoplasms typically associated with excellent long-term survival. Most recurrences occur within the first decade and are limited to the peritoneum. Nodal recurrence after several decades is exceedingly rare. Hormonal therapy is well-established in low-grade serous carcinoma (LGSC), but its role in borderline tumours remains undefined.</div></div><div><h3>Case presentation</h3><div>We describe the case of a 68-year-old woman with a history of advanced stage serous borderline ovarian tumour, previously treated surgically in the 1980s. After 37 years of disease-free survival, she presented with abdominopelvic pain and was found to have biopsy-confirmed recurrence in multiple nodal regions, including bilateral external iliac and mesenteric lymph nodes. Surgical debulking was performed, confirming SBT. The surgery was complicated by a left external iliac vein injury. Postoperatively, the course was complicated by extensive bilateral deep vein thromboses requiring long-term anticoagulation, as well as a left inguinal lymphocele. She subsequently developed progression in the right external iliac nodes eight months later. Due to surgical complexity, further resection was not pursued, and the patient was initiated on hormonal therapy with Tamoxifen. Follow-up imaging demonstrated partial response.</div></div><div><h3>Conclusion</h3><div>This case highlights the rare phenomenon of late nodal recurrence in borderline ovarian tumours and illustrates the potential role of hormonal therapy in selected cases where surgery is no longer feasible.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101960"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical HPV 18 detection is associated with high-grade cervical dysplasia in Kenyan and Ugandan women living with HIV","authors":"Miriam Nakalembe ,&nbsp;Collins Mpamani ,&nbsp;Jane Namugga ,&nbsp;Carolyn Nakisige ,&nbsp;Grace Banturaki ,&nbsp;Phillip Tonui ,&nbsp;Peter Itsura ,&nbsp;Omenge Orang’o ,&nbsp;Kapten Muthoka ,&nbsp;Anthony Ngeresa ,&nbsp;Beverly Musick ,&nbsp;Aaron Ermel ,&nbsp;Patrick Loehrer ,&nbsp;Darron R. Brown ,&nbsp;Yan Tong","doi":"10.1016/j.gore.2025.101953","DOIUrl":"10.1016/j.gore.2025.101953","url":null,"abstract":"<div><h3>Objectives</h3><div>Cervical cancer, caused by “high-risk” (HR) HPV, is the most common malignancy and the leading cause of cancer deaths among women living in Kenya and Uganda. Women living with HIV (WLWH) are at a high risk for HR-HPV infection. This longitudinal, observational cohort analysis was conducted to identify factors that are important among WLWH in prediction of cervical intraepithelial neoplasia grades 2 or 3 (CIN2/3).</div></div><div><h3>Methods</h3><div>Data of this analysis was based on a study of HPV natural history and cervical cancer among Kenyan and Ugandan WLWH. Demographic, behavioral and biological data were collected; HR-HPV DNA testing of cervical swabs was performed (Roche Cobas Assay); all WLWH underwent cervical biopsy on two occasions.</div></div><div><h3>Results</h3><div>Of 114 WLWH enrolled, the median age was 38.2 years. All WLWH were receiving ART during the study. CIN2/3 was found in 13 (11.4 %) WLWH; HPV 16 was detected in 10 (8.8 %); HPV 18 in 11 (9.6 %), and Non-16/18 HR-HPV in 62 (54.4 %). Aflatoxin exposure was not associated with CIN2/3 in this analysis. A multivariable logistic regression found that cervical detection of HPV 18 was significantly associated with CIN2/3 (OR = 6.36, 95 % CI = 1.36–29.75, p = 0.019), after adjusting for the effects of HIV viral load, CD4 counts, and Non-16/18 HR-HPV detection.</div></div><div><h3>Conclusions</h3><div>CIN2/3 was detected in 11.4% of WLWH; HPV 18 detection in cervical swabs was strongly associated with CIN2/3. Larger studies among WLWH are needed to determine optimal approaches for screening and treatment to prevent cervical cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101953"},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of molecular and immune signature on endometrial biopsies with atypical hyperplasia with and without concurrent endometroid carcinoma","authors":"Terrence Wong ,&nbsp;Joellen Fresia ,&nbsp;Nicholas Adzibolosu ,&nbsp;Logan Corey ,&nbsp;Sharon Wu ,&nbsp;Larissa Mattei ,&nbsp;Joanne Xiu ,&nbsp;Kurt Hodges ,&nbsp;Matthew Oberley ,&nbsp;Premal H. Thaker ,&nbsp;Rami Musallam ,&nbsp;Mira Kheil ,&nbsp;Sudeshna Bandyopadhyay ,&nbsp;Ira Winer ,&nbsp;Robert Morris ,&nbsp;Rouba Ali-Fehmi","doi":"10.1016/j.gore.2025.101959","DOIUrl":"10.1016/j.gore.2025.101959","url":null,"abstract":"<div><h3>Objective</h3><div>Patients with a biopsy diagnosis of atypical endometrial hyperplasia (AEH) or endometrial intraepithelial neoplasia (EIN) have a significant underlying risk of concurrent endometrial cancer (EC). We sought to determine whether molecular and/or immune signatures can be utilized to differentiate between pre-operative, premalignant lesions with and without concurrent occult endometrioid adenocarcinoma.</div></div><div><h3>Methods</h3><div>A single-institution database was queried for patients diagnosed with AEH/EIN on pre-operative sampling who then underwent subsequent hysterectomy. Whole exome and whole transcriptome sequencing of tissue samples were performed by CARIS Life Sciences. Quantification of immune cells from RNA sequencing data was estimated using quanTIseq.</div></div><div><h3>Results</h3><div>We identified 34 patients with matched pre-operative and hysterectomy specimens: 19 patients (56 %) with AEH/EIN only and 15 patients (44 %) with EC. Forty-four pathologic specimens (65 %) were successfully profiled. The most frequent genomic alterations in the EC cohort were PTEN (83.3 %), MSI-H (22.2 %), PIK3R1 (22.2 %), and CTNNB1 (16.7 %). There were no MSI-H or CTNNB1 alterations in the AEH/EIN cohort. Median expression of all ten immune checkpoint genes analyzed (CD80, CD86, CD274, CTLA4, HAVCR2/TIM3, IFNG, IDO1, LAG3, PDCD1, PDCD1LG2) were numerically higher for pre-operative biopsies in the EC cohort. Infiltrates of pro-tumorigenic regulatory T cells (+2.42 %) and tumor-suppressing neutrophils (+11.75 %) and CD8 + T cells (+2.39 %) trended higher (p &lt; 0.05) in this same cohort – absolute fractions of tumor-suppressing NK cells and M1 macrophages were also greater.</div></div><div><h3>Conclusions</h3><div>Pre-operative AEH/EIN biopsy specimens exhibit different molecular and immune profiles depending on the coexistence of concurrent EC. Further characterization of these signatures may lead to advances in diagnostic precision and prognostic capability.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101959"},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145154711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scholarly productivity during gynecologic oncology fellowship: A cross-sectional survey of graduates from 2020 to 2024","authors":"Glenn P. Boyles ,&nbsp;Chelsey I. Vranes ,&nbsp;Leslie H. Clark ,&nbsp;Kimberly Dessources ,&nbsp;J. Michael Straughn Jr","doi":"10.1016/j.gore.2025.101958","DOIUrl":"10.1016/j.gore.2025.101958","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize the scholarly accomplishments and attitudes regarding scholarly productivity among recent gynecologic oncology (GYO) fellowship graduates and identify factors which may influence academic productivity.</div></div><div><h3>Methods</h3><div>A 21-item web-based survey was distributed to individuals who had graduated from GYO fellowship within the past five years (2020–2024). Data on demographics, fellowship program characteristics, and scholarly accomplishments were collected. Descriptive statistics and univariate logistic regression were performed.</div></div><div><h3>Results</h3><div>115 individuals participated in the survey yielding a response rate of 31.2 %. The median number (min, max) of first-author published manuscripts was 4 (0, 18), conference posters was 4 (0, 30), and oral plenaries was 1 (0, 10). Graduates from programs with larger GYO clinical divisions were more likely to publish 4 or more first-author manuscripts compared to those from smaller divisions (OR 2.50; 95 % CI 1.09–5.74). The factors most frequently cited as supporting scholarly productivity were positive mentorship (65.4 %), access to existing databases (33.7 %), and timing of research year(s) (32.7 %). Reported barriers included clinical volume (63.5 %), inadequate technical support (36.5 %), and lack of mentorship (29.8 %). Fellows who had a clinical year prior to their dedicated research time were more likely to view timing of their research year(s) as contributory to their scholarly productivity (OR 2.89; 95 % CI 1.19–7.02).</div></div><div><h3>Conclusions</h3><div>This study provides valuable descriptive data on the scholarly accomplishments of recent GYO fellows. Clinical division size and timing of research year(s) seem to positively impact scholarly productivity.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101958"},"PeriodicalIF":1.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Ewing’s sarcoma of the vagina: A rare case report and literature review","authors":"Die Fan ,&nbsp;Xiaoxia Jiang ,&nbsp;Lin Wu ,&nbsp;Yujie Hao ,&nbsp;Chengbin Lu ,&nbsp;Zheng Li","doi":"10.1016/j.gore.2025.101949","DOIUrl":"10.1016/j.gore.2025.101949","url":null,"abstract":"<div><h3>Background</h3><div>Ewing’s sarcoma (ES) is an aggressive malignancy affecting bone and soft tissues, predominantly occurring in the skeletal system. The occurrence of Ewing’s sarcoma (ES) or primitive neuroectodermal tumor (PNET) with in the female genital tract is rare. Even rarer is its occurrence in the vagina, with only 22 cases reported to date. Accurate diagnosis necessitates a multifaceted approach that includes morphology, immunohistochemistry, and molecular pathology; the gold standard for diagnosis is next-generation sequencing (NGS), which is characterized by chromosomal translocations resulting in FET-ETS gene fusions.</div><div>Case description.</div><div>We present an exceptionally rare case of Ewing’s sarcoma in a 35-year-old woman of childbearing age. She exhibited a painless vaginal mass measuring approximately 2.5 × 2 × 0.9 cm, and according to the existing literature, our case represents the smallest tumor documented in primary vaginal Ewing’s sarcoma. Immunohistochemistry (IHC) revealed membrane positivity for CD99, along with positive expression of NKX2.2, FLI-1, and VIM. Furthermore, next-generation sequencing (NGS) conducted at the Affiliated Cancer Hospital of Fudan University identified an EWSR1-FLI1 gene fusion, thereby confirming the diagnosis of vaginal Ewing’s sarcoma.</div></div><div><h3>Conclusion</h3><div>Vaginal Ewing’s sarcoma is characterized by the absence of specific clinical manifestations and signs, along with a high rate of recurrence and metastasis. The management of these tumors primarily involves optimal local surgical intervention, followed by adjuvant therapies such as radiotherapy and/or chemotherapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101949"},"PeriodicalIF":1.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US","authors":"Premal H. Thaker ,&nbsp;Hui Lu ,&nbsp;Yitong J. Zhang ,&nbsp;Myrto Trapali ,&nbsp;Paul Swinburn ,&nbsp;Nicolas Krucien ,&nbsp;Doris White ,&nbsp;Joslyn Chaiprasert-Paguio ,&nbsp;Bhavana Pothuri ,&nbsp;Jie Ting","doi":"10.1016/j.gore.2025.101947","DOIUrl":"10.1016/j.gore.2025.101947","url":null,"abstract":"<div><h3>Objective</h3><div>This study assessed treatment preferences of patients with recurrent/metastatic cervical cancer, a disease with poor prognosis.</div></div><div><h3>Methods</h3><div>A survey with two discrete choice experiments was completed by 150 patients with recurrent/metastatic cervical cancer in the US. Discrete choice experiment 1 included treatment attributes, and discrete choice experiment 2 included risk mitigation plan attributes.</div></div><div><h3>Results</h3><div>Participants valued 12-month overall survival rate as the most important attribute, followed by disease control rate; both efficacy attributes were rated as more important than the risk of side effects such as peripheral neuropathy and corneal side effects. Participants’ willingness to accept a treatment profile requiring a risk mitigation plan was influenced by the number of clinic visits and out-of-pocket costs.</div></div><div><h3>Conclusions</h3><div>Patients with recurrent/metastatic cervical cancer prioritize overall survival and disease control rate as the most important attributes. These findings can be used to inform shared decision-making and treatment discussions among patients, clinicians, and the care team.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101947"},"PeriodicalIF":1.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}